Media Relations

Securing quality coverage in the global media (print, online and broadcast) of your company’s story is one of the main ways to gain visibility and ensure your messages reach the right audiences.

We specialise in writing and distributing press releases that resonate with top-tier financial and life sciences trade media to raise visibility and build your company’s reputation. We have the relationships and media pitching experience needed to secure interviews and meaningful coverage. We also ensure that spokespeople are thoroughly prepared and equipped with Q&A materials to support successful outcomes that drive company value.

Services

Message development
Press releases
Question and answer documents
Media interviews
Media relations
Media training
Media factsheets
Social media campaigns
Thought leader articles

Case Studies

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

Epitopea USD $31 Million Pre-Series A Financing

Supporting Epitopea’s $31M Pre-Series A financing with high-impact media coverage, raising visibility for CryptoMap™ and strengthening investor and partner engagement.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | Submission for FDA 510(k) Clearance

Supporting LEX’s dual FDA submissions and takeover bid with strategic media outreach and strong trade coverage.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment

Strategic support to amplify MONCYTE Health’s €1M seed round and boost visibility among investors and industry stakeholders.

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

Epitopea USD $31 Million Pre-Series A Financing

Supporting Epitopea’s $31M Pre-Series A financing with high-impact media coverage, raising visibility for CryptoMap™ and strengthening investor and partner engagement.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | Submission for FDA 510(k) Clearance

Supporting LEX’s dual FDA submissions and takeover bid with strategic media outreach and strong trade coverage.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment

Strategic support to amplify MONCYTE Health’s €1M seed round and boost visibility among investors and industry stakeholders.

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform